Statement from Michael Sapienza, CEO of the Colon Cancer Alliance, on FDA Approval of VARUBI Intravenous Administration
October 26, 2017 (WASHINGTON)–VARUBI, a highly anticipated treatment for colorectal patients who suffer from delayed chemotherapy-induced nausea, has been approved by the Food and Drug Administration for delivery via one-time intravenous administration. This new way to administer VARUBI provides healthcare providers with flexibility to treat patients in a more individualized manner.
VARUBI addresses delayed nausea that can arrive 24 to 120 hours after the start of chemotherapy. If nausea is not managed aggressively, it can lead to weight loss, dehydration, and hospitalization. Quality-of-life issues are incredibly important for patients and families dealing with colorectal cancer and chemotherapy. The approval of VARUBI is good step forward in addresses some of these concerns.
For more information about VARUBI, please access:
https://globenewswire.com/news-release/2017/10/25/1153687/0/en/TESARO-Announces-U-S-FDA-Approval-of-VARUBI-IV-for-Delayed-Nausea-and-Vomiting-Associated-With-Cancer-Chemotherapy.html
Top resources
Alliance Launches PSA to Promote Resources & Prevention
The new initiative raises awareness of Colorectal Cancer Alliance support services and screening to curb the rising rates of colorectal cancer, the second deadliest cancer in the U.S.
Volunteer spotlight: Christine Rizk
In this Q&A, get to know Christine Rizk, a passionate and dedicated Colorectal Cancer Alliance volunteer from Phoenix.
Legislation introduced to address young-onset CRC
Explore the urgent need for the Colorectal Cancer Early Detection Act (HR 7714), legislation aimed at combating the rising incidence of colorectal cancer among younger adults through enhanced screening, education, and research.